Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market Report 2019-2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023”
report has been added to ResearchAndMarkets.com’s
offering.

The attention deficit hyperactivity disorder (ADHD) drugs market will
register a CAGR of almost 6% by 2023.

The rising incidence rate of ADHD among children is one of the critical
factors that will trigger the growth of the attention deficit
hyperactivity disorder drugs market. The expansion of the patient pool
with positive ADHD symptoms is fueling the demand for ADHD therapies. As
per the CDC, in 2016. Approximately 9.4% of children aged 2-17 years
were diagnosed with ADHD. Thus, a significant patient pool (aged between
12 and 17 years) rely on medications. This is expected to rise further
with the increasing prevalence of the disease, thereby contributing to
the growth of the market during the forecast period.

Market Overview

Rising government support

The global ADHD drugs market is currently witnessing an increase in the
number of government initiatives to promote the awareness of the disease
and to fund drug development in the area of mental health therapeutics.
Additionally, the Centers for Disease Control and Prevention (CDC)
supports the National Resource Center (NRC) on ADHD, a program designed
to help children and adults with ADHD. The NRC program provides
information, resources, and advice to parents on how to help their
children with ADHD. Thus, the rising government support to help people
with ADHD is expected to drive the growth of the market during the
forecast period.

Lack of patient compliance with ADHD treatment

The pharmacological (medications) treatment with neuro-stimulant drugs
is considered as the gold standard for the treatment of ADHD in children
and adults. However, the multiple dosing regimens associated with
neuro-stimulant drugs, such as methylphenidate and amphetamine, and the
timely dosing and long duration of the treatment are leading to a
decrease in the patient compliance with these drugs. This leads to a
decline in the consumption of ADHD drugs, thereby impeding the growth of
the market.

Competitive Landscape

The market appears to be highly fragmented. The presence of several
companies, including Johnson & Johnson Services Inc. and NEOS
Therapeutics Inc. makes the competitive environment quite intense.
Factors such as the rising incidence rate of ADHD among children and the
increasing government support will provide considerable growth
opportunities to attention deficit hyperactivity disorder drugs
manufactures. Amneal Pharmaceuticals Inc., Eli Lilly and Co., and Takeda
Pharmaceutical Co. Ltd. are some of the major companies covered in this
report.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

Preface

Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Stimulants – Market size and forecast 2018-2023

Non-stimulants – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

• Amneal Pharmaceuticals Inc.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• NEOS Therapeutics Inc.
• Takeda Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/adaglh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Disorders Drugs